Evidence map›Paper›PMID 35643306›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2022

TNF-related apoptosis-inducing ligand, interferon gamma-induced protein 10, and C-reactive protein in predicting the progression of SARS-CoV-2 infection: a prospective cohort study.

Sina A Tegethoff, Guy Danziger, Dennis Kühn, Charlotte Kimmer, Thomas Adams, Lena Heintz, Carlos Metz, Katharina Reifenrath, Rebecca Angresius, Sebastian Mang and 19 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04655521 (The Dynamics of the Immune Response to Infection by SARS Coronavirus 2), which is not on this map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04655521 completednot on this map

The Dynamics of the Immune Response to Infection by SARS Coronavirus 2

TypeobservationalSponsorUniversität des SaarlandesRan2020 to 2021Enrolled173ConditionsCOVID-19, SARS-CoV-2, Viral Infection
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Expression ofFuture virology · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 4 institutions in 1 country.

Sina A TegethoffCentre for Infectious Diseases, Institute of Medical Microbiology and Hygiene, Saarland University, Homburg, Germany.
Guy DanzigerDepartment of Medicine V: Pneumology, Allergology and Intensive Care Medicine, ECLS Centre Saar, Saarland University Medical Centre, Saarland University, Homburg, Germany.
Dennis KühnCentre for Infectious Diseases, Institute of Medical Microbiology and Hygiene, Saarland University, Homburg, Germany; Department of Medicine V: Pneumology, Allergology and Intensive Care Medicine, ECLS Centre Saar, Saarland University Medical Centre, Saarland University, Homburg, Germany.
Charlotte KimmerCentre for Infectious Diseases, Institute of Medical Microbiology and Hygiene, Saarland University, Homburg, Germany.
Thomas AdamsDepartment of Medicine II, Saarland University Medical Centre, Saarland University, Homburg, Germany.
Lena HeintzDepartment of Medicine II, Saarland University Medical Centre, Saarland University, Homburg, Germany.
Carlos MetzDepartment of Medicine V: Pneumology, Allergology and Intensive Care Medicine, ECLS Centre Saar, Saarland University Medical Centre, Saarland University, Homburg, Germany.
Katharina ReifenrathCentre for Infectious Diseases, Institute of Medical Microbiology and Hygiene, Saarland University, Homburg, Germany; Department of Medicine II, Saarland University Medical Centre, Saarland University, Homburg, Germany.
Rebecca AngresiusDepartment of Medicine II, Saarland University Medical Centre, Saarland University, Homburg, Germany.
Sebastian MangDepartment of Medicine V: Pneumology, Allergology and Intensive Care Medicine, ECLS Centre Saar, Saarland University Medical Centre, Saarland University, Homburg, Germany.
Torben RixeckerDepartment of Medicine V: Pneumology, Allergology and Intensive Care Medicine, ECLS Centre Saar, Saarland University Medical Centre, Saarland University, Homburg, Germany.
André BeckerDepartment of Medicine V: Pneumology, Allergology and Intensive Care Medicine, ECLS Centre Saar, Saarland University Medical Centre, Saarland University, Homburg, Germany.
Jürgen GeiselDepartment of Clinical Chemistry and Laboratory Medicine, Saarland University Medical Centre, Saarland University, Homburg, Germany.
Christophe JentgenDepartment of Medicine V: Pneumology, Allergology and Intensive Care Medicine, ECLS Centre Saar, Saarland University Medical Centre, Saarland University, Homburg, Germany.
Frederik SeilerDepartment of Medicine V: Pneumology, Allergology and Intensive Care Medicine, ECLS Centre Saar, Saarland University Medical Centre, Saarland University, Homburg, Germany.
Matthias C ReichertDepartment of Medicine II, Saarland University Medical Centre, Saarland University, Homburg, Germany.
Franziska FröhlichCentre for Infectious Diseases, Institute of Medical Microbiology and Hygiene, Saarland University, Homburg, Germany; Department of General Paediatrics and Neonatology, Saarland University, Homburg, Germany.
Sascha MeyerDepartment of General Paediatrics and Neonatology, Saarland University, Homburg, Germany.
Jürgen RisslandCentre for Infectious Diseases, Institute of Virology, Saarland University Medical Centre, Homburg, Germany.
Sebastian EwenDepartment of Emergency Medicine, Saarland University Medical Centre, Saarland University, Homburg, Germany.
Gudrun WagenpfeilInstitute of Medical Biometry, Epidemiology and Medical Informatics, Saarland University, Homburg, Germany.
Katharina LastCentre for Infectious Diseases, Institute of Medical Microbiology and Hygiene, Saarland University, Homburg, Germany.
Sigrun SmolaCentre for Infectious Diseases, Institute of Virology, Saarland University Medical Centre, Homburg, Germany; Helmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research, Saarland University Campus, Saarbrücken, Germany.
Robert BalsDepartment of Medicine V: Pneumology, Allergology and Intensive Care Medicine, ECLS Centre Saar, Saarland University Medical Centre, Saarland University, Homburg, Germany.
Frank LammertDepartment of Medicine II, Saarland University Medical Centre, Saarland University, Homburg, Germany; Hannover Medical School (MHH), Hannover, Germany.
Sören L BeckerCentre for Infectious Diseases, Institute of Medical Microbiology and Hygiene, Saarland University, Homburg, Germany.
Marcin KrawczykDepartment of Medicine II, Saarland University Medical Centre, Saarland University, Homburg, Germany.
Philipp M LepperDepartment of Medicine V: Pneumology, Allergology and Intensive Care Medicine, ECLS Centre Saar, Saarland University Medical Centre, Saarland University, Homburg, Germany.
Cihan PapanCentre for Infectious Diseases, Institute of Medical Microbiology and Hygiene, Saarland University, Homburg, Germany. Electronic address: cihan.papan@uks.eu.
Saarland University · DEInstitute of Medical Microbiology and Hygiene · DEHelmholtz Centre for Infection Research · DEMedizinische Hochschule Hannover · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEarly prognostication of COVID-19 severity will potentially improve patient care. Biomarkers, such as TNF-related apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein 10 (IP-10), and C-reactive protein (CRP), might represent possible tools for point-of-care testing and severity prediction.

methodsIn this prospective cohort study, we analyzed serum levels of TRAIL, IP-10, and CRP in patients with COVID-19, compared them with control subjects, and investigated the association with disease severity.

resultsA total of 899 measurements were performed in 132 patients (mean age 64 years, 40.2% females). Among patients with COVID-19, TRAIL levels were lower (49.5 vs 87 pg/ml, P = 0.0142), whereas IP-10 and CRP showed higher levels (667.5 vs 127 pg/ml, P <0.001; 75.3 vs 1.6 mg/l, P <0.001) than healthy controls. TRAIL yielded an inverse correlation with length of hospital and intensive care unit (ICU) stay, Simplified Acute Physiology Score II, and National Early Warning Score, and IP-10 showed a positive correlation with disease severity. Multivariable regression revealed that obesity (adjusted odds ratio [aOR] 5.434, 95% confidence interval [CI] 1.005-29.38), CRP (aOR 1.014, 95% CI 1.002-1.027), and peak IP-10 (aOR 1.001, 95% CI 1.00-1.002) were independent predictors of in-ICU mortality.

conclusionsWe demonstrated a correlation between COVID-19 severity and TRAIL, IP-10, and CRP. Multivariable regression showed a role for IP-10 in predicting unfavourable outcomes, such as in-ICU mortality.

trial registrationClinicaltrials.gov, NCT04655521.

Indexed as

COVID-19C-Reactive ProteinChemokine CXCL10FemaleHumansIntensive Care UnitsInterferon-gammaMaleMiddle AgedProspective StudiesSARS-CoV-2TNF-Related Apoptosis-Inducing LigandChemokine CXCL10C-Reactive ProteinInterferon-gammaTNF-Related Apoptosis-Inducing LigandBiomarkersCOVID-19CRPHost responseIP-10Point-of-care testingSeverity predictionTRAIL

Identifiers

PMID35643306
PMCPMC9132472
OpenAlexW4281558389

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.